US regulators have posted a safety statement warning of an increased risk of death for patients receiving AbbVie’s venetoclax with bortezomib and dexamethasone for melanoma patients.
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.